证券代码：600332 证券简称：白云山 公告编号：2025—042 广州白云山医药集团股份有限公司 关于子公司通过高新技术企业认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广西白云山盈康药业有限公司（以下简称"广西盈康"）已通 过高新技术企业重新认定，并收到由广西壮族自治区科学技术厅、广 西壮族自治区财政厅、国家税务总局广西壮族自治区税务局联合颁发 的《高新技术企业证书》，证书有关信息具体如下： 企业名称：广西白云山盈康药业有限公司 证书编号：GR202445000589 发证日期：2024年12月7日 有效期：三年 广西盈康通过高新技术企业认定后，根据国家的相关规定，自获 得高新技术企业认定后连续三年内（2024年、2025年和2026年）可享 受国家关于高新技术企业的相关优惠政策，即按15%的税率缴纳企业 所得税。2024年本公司已按照15%的所得税税率计缴该公司所得税。 本次广西盈康获得《高新技术企业证书》不会对本公司当期经营业绩 产生重大 ...

Group 1 - Recent demand for home testing and antiviral medications has surged, with COVID-19 antigen search demand in Beijing, Shanghai, Guangzhou, and Shenzhen increasing by 3-5 times compared to the previous week [1] - Home testing service orders on Meituan have increased by 30% year-on-year over the past four days, while orders for COVID-related antiviral medications have more than doubled compared to the previous week [1] - Meituan Health has launched a special public welfare program in collaboration with Wanfang Biological and medical device merchants, allowing users to purchase COVID-19 antigen test kits for just one cent, targeting high-demand cities [1] Group 2 - Guangzhou Pharmaceutical Group's subsidiary, Baiyunshan and Huang Zhong Medicine, reports that current production capacity can meet market demand for antiviral drugs [2] - The company has collaborated with academic experts for over ten years, discovering that Banlangen has multi-target antiviral properties and can help regulate excessive immune responses [2] - The formulation of Kouyanqing granules, which includes various traditional Chinese medicinal ingredients, is effective in treating oral and throat diseases, potentially alleviating symptoms of pharyngitis [2]

Core Viewpoint - Guangzhou Pharmaceutical Co., Ltd. (referred to as "Guangzhou Medicine") will be listed on the National Equities Exchange and Quotations (NEEQ) starting May 20, 2025, after previously attempting an IPO in Hong Kong without success [1][2]. Group 1: Company Overview - Guangzhou Medicine, established in 1951, is the largest pharmaceutical distribution company in South China, engaging in wholesale and retail of pharmaceuticals, including Western medicine, traditional Chinese medicine, and medical devices, with over 1,700 employees [2]. - White Cloud Mountain Pharmaceutical Group Co., Ltd. (referred to as "White Cloud Mountain") holds a 90.92% stake in Guangzhou Medicine, making it the controlling shareholder [2]. Group 2: Financial Performance - Guangzhou Medicine's revenue for 2023 and 2024 is projected to be 52.591 billion yuan and 54.605 billion yuan, respectively, with net profits of 649 million yuan and 578 million yuan [2]. - In contrast, White Cloud Mountain reported a decline in net profit for 2024, reaching 2.835 billion yuan, a decrease of 30.09% year-on-year, with total revenue of 74.993 billion yuan, down 0.69% [4]. Group 3: Strategic Decisions - The decision to list Guangzhou Medicine on the NEEQ follows the termination of its H-share listing plans due to changes in market conditions and the expiration of regulatory approvals [2]. - White Cloud Mountain stated that the new listing will not adversely affect its financial status or operational results, as Guangzhou Medicine will remain a consolidated subsidiary [3]. Group 4: Challenges and Considerations - White Cloud Mountain's financial difficulties, including significant impairment provisions totaling approximately 471 million yuan, may impact Guangzhou Medicine's future fundraising efforts [5]. - The company faces challenges from industry policy changes and intense market competition, raising questions about its plans for product structure optimization and cost control [5].

Group 1 - Baiyunshan Holdings' subsidiary Guangzhou Pharmaceutical Co., Ltd. will be listed on the New Third Board starting May 20, 2025, marking a significant step in capital operations for Baiyunshan [1] - The listing is expected to broaden financing channels and enhance brand influence, as Guangzhou Pharmaceutical is a leading pharmaceutical distribution company in South China [1] - However, the New Third Board has relatively low liquidity, necessitating the optimization of governance structures and strengthening of profitability to attract long-term capital [1] Group 2 - Dezhan Health has signed a cooperation framework agreement with Academician Yang Baofeng to establish an academician expert workstation at its subsidiary, Deyi Pharmaceutical Co., Ltd. [2] - This collaboration aims to enhance the company's drug development capabilities in the cannabinoid innovation drug field [2] - The development of cannabinoid drugs is noted to have long cycles and strict regulations, requiring attention to clinical progress and commercialization capabilities [2] Group 3 - BeiGene has registered a Phase Ib clinical trial for BGB-16673, a BTK degrader targeting chronic spontaneous urticaria, marking it as the first autoimmune disease trial for this drug [3] - BGB-16673 is the fastest progressing BTK degrader in clinical development and has the potential to address resistance issues associated with existing BTK inhibitors [3] - The expansion into autoimmune indications opens up broader market opportunities and validates the application potential of the CDAC platform across multiple disease areas [3]

药品行业趋势快报 2025年1-4月 数据来源 p 硬广统计平台：央卫视49频道（2024年4月1日起新增CCTV-17农业农村频道监测，共计49个央卫视频道） p 综艺统计平台：电综：央卫视49频道（2024年4月1日起新增CCTV-17农业农村频道监测，共计49个央卫视频道） 网综-爱优腾芒等主流视频平台 p 网剧统计平台：爱奇艺、优酷、腾讯视频、芒果TV等四大平台，剧集播出首轮品牌监测 p 网剧合作类型：剧内植入-影视剧剧内品牌植入，指口播、片尾鸣谢、置景道具、互动道具等资源；平台自招商：指 标板、角标、预告/回顾、创可贴、创意中插、片尾彩蛋、明星播报、压屏条、内容提示等资源 p 报告中客户数量均按照厂商数统计；报告中去除非商业合作客户：音乐、视频、场地合作、新浪等非商业客户 p 报告统计周期：2025年1月-4月 硬广-药品客户在央视系列频道投放数量及时长均领先，投放时长占比超58% 数据来源：击壤科技 2025年1-4月 央卫视49频道硬广 • 截至25年4月，药品硬广客户数（厂商数）共计191个，投放时长总计3,214,104 秒；从媒体层级看，多投放央视系列频道，央视频道投放时长占比高达58.1 ...

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors on recent corporate actions and developments. Group 1: Corporate Announcements - Kweichow Moutai's shareholders approved a profit distribution plan for 2024, proposing a cash dividend of 276.24 yuan per 10 shares, totaling 34.672 billion yuan [3] - Weir Shares plans to change its name to "Haowei Group" and its stock abbreviation to "Haowei Group," pending shareholder approval [4] - Weili intends to transfer 100% equity of its subsidiary Dunhua Zhongneng to Chengfa Environment for a total consideration of approximately 323 million yuan [6] - Wanrun New Energy signed a business cooperation agreement with CATL to supply lithium iron phosphate products, with an estimated total supply of about 1.3231 million tons from 2025 to 2030 [7] - Shouhua Gas plans to purchase bauxite resources through market means, with a financing application of up to 2 billion yuan [8] Group 2: Regulatory and Compliance - Gao Neng Environment received an administrative regulatory decision from the Beijing Securities Regulatory Bureau due to insufficient impairment testing and inaccurate disclosures [9] - ST Shilong applied to revoke its other risk warning status, indicating compliance with relevant regulations [14] Group 3: Mergers and Acquisitions - Huixin Electronics plans to acquire 67.91% of Baode Computer through a combination of cash and stock issuance, enhancing its position in the IT infrastructure sector [19] - Kangping Technology intends to acquire 100% of Sulu Electronics for 198 million yuan to expand its electric tools business [23] - Xinjiang Haoyuan plans to change its name to "Wanqing Energy" to better reflect its business structure [26] Group 4: Financing and Investments - Shanghai Xinyang plans to invest 30 million yuan in the establishment of the Qixin Fund, focusing on high-tech sectors [12] - Taihe Co. intends to invest up to 150 million USD (approximately 1.082 billion yuan) in a pesticide and functional chemicals project in Egypt [28] Group 5: Strategic Partnerships and Contracts - Dongzhu Ecology signed a 3.5 billion yuan EPC contract for land consolidation in Laos [30] - Youa Co. signed a strategic cooperation framework agreement with Changsha Guokong Capital and Tsinghua Electronics Institute to promote the semiconductor industry [32] Group 6: Shareholder Actions - Wanfeng Co. plans to reduce its stake by up to 1.75% through block trading [35] - Tuoershi's controlling shareholder intends to reduce its stake by up to 2% [36]

Group 1 - Company Weili plans to transfer 100% equity of its wholly-owned subsidiary Dunhua Zhongneng Environmental Power Co., Ltd. to Chengfa Environment for a total consideration of approximately 323 million yuan, which includes a transfer price of 100 million yuan and shareholder loans of about 223 million yuan [3] - Company Wanrun New Energy has signed a business cooperation agreement with CATL to supply lithium iron phosphate products, with an estimated total supply of approximately 1.32 million tons from May 2025 to 2030, and a commitment for monthly procurement of at least 80% of the agreed supply [4] - Company Shouhua Gas intends to purchase bauxite resources through market-based methods, with a purchase amount not exceeding 30% of the latest audited total assets or 100% of net assets within 12 months [5] Group 2 - Company Gaon Environment received an administrative regulatory decision from the Beijing Securities Regulatory Bureau due to insufficient basis for goodwill impairment and inaccurate disclosure of related party transactions, resulting in a warning letter issued to the company and its key personnel [6] - Company Hongxin Electronics' subsidiary signed two contracts for computing power services and hardware procurement, with total contract amounts of 177 million yuan and 385 million yuan respectively, enhancing the company's market share in the AI business [7] - Company Shanghai Xinyang plans to invest 30 million yuan in the establishment of the Qixin Fund, focusing on investments in semiconductor, integrated circuits, AI, new materials, and advanced manufacturing sectors [8] Group 3 - Company Baiyunshan's subsidiary Guangzhou Pharmaceutical will be listed on the New Third Board starting May 20, 2025 [9] - Company Jincheng signed a service agreement for underground mining operations at the Komakau Copper Mine, with a total contract value of approximately 805 million USD over a five-year period [11] - Company Dongzhu Ecology signed an EPC general contracting agreement worth approximately 3.5 billion yuan for a land consolidation project in Laos, with a contract duration of three years [12] Group 4 - Company Youa signed a strategic cooperation framework agreement with Changsha Guokong Capital and Tsinghua Electronics Institute to promote the semiconductor industry upgrade in Changsha [13] Group 5 - Company Wanfeng plans to reduce its shareholding by up to 1.75% through block trading [15] - Company Hexing Packaging intends to repurchase shares worth between 50 million to 100 million yuan for employee stock ownership plans, with a maximum repurchase price of 4.67 yuan per share [17] - Company Zhaoxun Media plans to repurchase shares worth between 100 million to 200 million yuan for employee stock ownership plans, with a maximum repurchase price of 14.8 yuan per share [18]

Core Viewpoint - The article emphasizes the integration of party building and industrial revitalization as a driving force for rural revitalization, particularly through the collaboration between Guangzhou Wanglaoji Health Industry Co., Ltd. and local villages in the cultivation of "Xian Cao" (a type of herb) [2][4][19]. Group 1: Party Building and Collaboration - The work teams from the Guangdong Provincial Market Supervision Administration are actively implementing measures to promote the cultivation of Xian Cao in Changtan Town, Biaoling County, in partnership with Wanglaoji [3][4]. - A party branch co-construction agreement was signed between Wanglaoji and local village party committees, focusing on collaborative development and resource sharing [10][11][19]. - The training sessions led by local party leaders emphasize the importance of the Central Eight Regulations, aiming to enhance party discipline and improve the relationship between party members and the community [22][24]. Group 2: Industrial Support and Development - The collaboration aims to leverage local resources to develop the Xian Cao industry, addressing questions about the feasibility of cultivation and market access for local farmers [28][30]. - A comprehensive training program was organized to educate farmers on Xian Cao cultivation techniques, which is expected to improve yield and quality while fostering a new generation of skilled growers [41][44]. - The establishment of the "Xiali Xiang Planting and Breeding Cooperative" aims to create a cooperative model that integrates management, farming, and corporate support, enhancing the overall efficiency of the Xian Cao industry [47][50]. Group 3: Project Implementation and Progress - The work teams have initiated the construction of Xian Cao planting bases, with approximately 200 acres established and over 600,000 seedlings planted [56]. - The current growth status of the Xian Cao indicates a healthy development, with plants reaching a height of 30 centimeters [57]. - Future plans include the establishment of a complete industrial chain for Xian Cao, integrating planting, processing, and storage, to serve as a model for rural revitalization [59][60].

Group 1 - The core viewpoint of the article highlights the decline of the artemisinin concept sector, which fell by 0.82%, ranking among the top declines in the concept sector [1][2] - Within the artemisinin concept sector, major companies such as Rundu Co., Zhejiang Medicine, and Kunming Pharmaceutical experienced significant declines, while only two stocks, Delong Huineng and Baiyunshan, saw increases of 1.06% and 0.37% respectively [1][2] - The article provides a detailed overview of the capital flow, indicating a net outflow of 58 million yuan from the artemisinin concept sector, with Rundu Co. leading the outflow at 43.43 million yuan [2] Group 2 - The article lists the top-performing concept sectors, with the military equipment restructuring concept leading with a gain of 3.92%, while the artemisinin concept was among the worst performers [2] - A table is provided showing the capital flow for various companies within the artemisinin concept, detailing their respective price changes and turnover rates, with Rundu Co. showing a significant outflow [2]

证券代码：874839 证券代码：600332 证券简称：白云山 公告编号：2025－041 广州白云山医药集团股份有限公司 关于控股子公司广州医药股份有限公司 在新三板正式挂牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）近日收到控股子公 司广州医药股份有限公司（"广州医药"）通知，广州医药股票将于 2025 年 5 月 20 日起在全国中小企业股份转让系统（"新三板"）挂牌并公开 转让，相关信息如下： 证券简称：广州医药 交易方式：集合竞价交易 所属层级：创新层 广州医药公开转让说明书已于2025年4月29日在全国中小企业股份 转让系统指定信息披露平台（www.neeq.com.cn 或 www.neeq.cc）上进行 披露，供投资者查阅。 特此公告。 广州白云山医药集团股份有限公司董事会 2025 年 5 月 19 日 1 ...